Proposing DAPP-MR as a disaster risk management pathways framework for complex, dynamic multi-risk.

Climate change impacts are increasingly complex owing to compounding, interacting, and cascading risks across sectors. However, approaches to support Disaster Risk Management (DRM) addressing the underlying (uncertain) risk driver interactions are still lacking. We tailor the approach of Dynamic Adaptive Policy Pathways (DAPP) to DAPP-MR to design DRM pathways for complex, dynamic multi-risk in multi-sector systems.

Isoprinosine increases the antitumor action of interferon.

The association of relatively low doses of interferon with an immunostimulant, isoprinosine, enhanced the antitumor effect of interferon. Each mouse was inoculated with 10(6) Crocker Tumor 180/TG cells. The best results were obtained when both interferon and isoprinosine were injected three times a week for 1 month.

Isoprinosine increases the antitumor action of interferon.

The association of relatively low doses of interferon with an immunostimulant (isoprinosine) enhances the antitumor effect of interferon. After combined treatment, the mean survival time, tumor incidence, and final survival rate are significantly increased in mice inoculated with 10(6) Crocker tumor 180/TG cells when compared to mice treated with interferon alone.

[Mathematical simulation model of cardiac contraction].

The authors describe a mathematical model simulating cardiac contraction based onMaxwell's well known analogue model. The general equations of the model are presented and discussed in relation to published findings. The functioning and compute application of the model are briefly described.

Follow-up of the first (1962) pilot study of active immunotherapy of acute lymphoid leukaemia: a critical discussion.

The follow-up of the first active immunotherapy (AI) controlled pilot study on acute lymphoid leukaemia (ALL), started in 1962, is reported: seven patients out of 20 are still in first remission and eight of the AI group are still alive between 10 and 13 years later, while all ten controls have relapsed and died. The methodology of this pilot study is discussed, as well as the results of the later AI trials conducted on ALL. In the light of a critical discussion and of the further trials conducted by the authors or published in the literature, the authors conclude that A1 is efficient in ALL and that its use is indicated as, in several trials, it has been as active as maintenance chemotherapy, as it has induced no deaths in 300 patients contrary to maintenance chemotherapy, which has been responsible for 4 to 28% of deaths in patients in complete remission, and as the authors have registered no late relapses after three years in the AI trials, while such relapses appear in most maintenance chemotherapy trials.

[Active immunotherapy of acute leukemia and leukemic lymphosarcoma. Results of 10 years. Study of 200 cases].

The authors report a ten year study of active immunotherapy using BCG and irradiated allogeneic leukaemic cells in 200 patients. In acute lymphatic leukaemia, 57 out of 168 patients treated in this way remained in primary remission for 18 months to 10 years after active immunotherapy was begun, the relapse rate became low after 18 months and nil after 36 months. The results varied according to prognostic factors: the cytological type, active immunotherapy being above all effective in small cell (microlymphoblastic and prolymphocytic) types with a hope of cure in 50 to 60 p.

Leukaemic conversion of non-Hodgkin's malignant lymphomata.

In 143 patients with poorly differentiated lymphosarcoma, leukaemic conversion has been observed in 25. The cytological type was prolymphocytic or lymphoblastic or lymphoblastoid (immunoblastic ?). Twenty-five patients were treated with chemo-radiotherapy, followed by active immunotherapy as if they had primary acute lymphoid leukaemia.

Cytology in the classification of diffuse non-leukaemic malignant lymphomata (lympho- and reticulosarcomata).

Cytological examination of smears or imprints of diffuse non-leukaemic lymphomata gives more details of the morphological aspects of the cells than does histological examination. It enables us to distinguish (a) prolymphocytic (but not lymphocytic), (b) lymphoblastic or lymphoblastoid and immunoblastic lymphosarcomata. It helps to diagnose so-called reticulosarcomata from carcinomata and to distinguish two types: (a) cytic and (b) blastic, but it makes us suspicious about the nature of the latter.

Hydroxyurea, leucopheresis, and splenectomy in chronic myeloid leukaemia at the problastic phase.

Forty-three patients with chronic myeloid leukaemia have been treated with hydroxyurea in order to be subjected to leucopheresis for white cell transfusions. Hydroxyurea decreases leucocytosis when it is administered and the blood granulocyte number increases soon after the drug is stopped. The survival of the patients is not different from the survival of the patients treated with conventional chemotherapy (busulphan, mitobronitol) and it is superior to the survival of patients treated with external radiotherapy or with (32)P.

The two varieties of lymphoid tissue "reticulosarcomas", histiocytic and histioblastic types.

On the basis of histological sections and cytological smears in 110 cases, the "reticulosarcoma" (exclusive of Ewing's sarcoma and reticulosarcomas of bone marrow) were divided into two varieties: histiocytic types and histioblastic types.The correlation between the histological and cytological evaluation was excellent in each case; only those tumours classified as histiocytic presented a continuous and abundant network of reticulin.The histioblastic type predominated in the male sex.